Related Experiment Video
Updated: Aug 15, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Cellular angiofibroma of the vulva: report of a case
Y Dikmen1, M S Yucebilgin, M Kazandi
1Department of Obstetrics and Gynecology, Ege University Faculty of Medicine, Bornova, Izmir, Turkey.
Insights
This case study details a vulvar cellular angiofibroma in a 50-year-old woman. Immunohistochemistry confirmed CD34 positivity, aiding diagnosis of this rare soft tissue tumor.
Area of Science:
- Gynecologic pathology
- Soft tissue tumor research
Background:
- Cellular angiofibroma is a rare mesenchymal neoplasm.
- Vulvar localization of this tumor is uncommon.
Observation:
- A 50-year-old woman presented with a four-year history of a right labial mass.
- Surgical excision was performed for the labial mass.
Findings:
- Histopathological examination confirmed the features of cellular angiofibroma.
- Immunohistochemical analysis showed the tumor was CD34 positive.
- The lesion was non-reactive for desmin, smooth muscle actin, and S-100 protein.
Implications:
- This case highlights cellular angiofibroma as a differential diagnosis for vulvar soft tissue tumors.
- Accurate immunohistochemical profiling is crucial for diagnosing this entity.
- Further research may elucidate the specific behavior and origin of vulvar cellular angiofibromas.
Abstract:
A case of vulvar cellular angiofibroma in a 50-year-old woman was immunohistochemically examined. She presented with a right labial mass which was noticed four years before. Surgical excision of the mass was performed. Histopathological examination revealed typical characteristics of cellular angiofibroma. Immunohistochemically, the lesion was CD34 positive but non-reactive for desmin, smooth muscle actin and S-100 protein. In this article, we present a case of vulvar cellular angiofibroma, a lesion that should be considered in the differential diagnosis of vulvar soft tissue tumors.
